Health Care [ 9/12 ] | Biotechnology [ 58/73 ]
NASDAQ | Common Stock
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity.
Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 25 | -0.80 Increased by +25.23% | -0.90 Increased by +11.46% |
| Mar 4, 25 | -1.03 Decreased by -21.18% | -1.02 Decreased by -0.82% |
| Nov 5, 24 | -1.05 Decreased by -16.83% | -0.89 Decreased by -18.15% |
| Aug 8, 24 | -0.18 Increased by +81.25% | -1.04 Increased by +82.69% |
| May 10, 24 | -1.07 Decreased by -143.18% | -1.26 Increased by +15.08% |
| Mar 6, 24 | -0.85 Decreased by -251.79% | -1.03 Increased by +17.48% |
| Nov 7, 23 | -0.90 Decreased by -3.10 K% | -1.20 Increased by +25.00% |
| Aug 8, 23 | -0.96 Decreased by -740.00% | -1.03 Increased by +6.80% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -34.61 M Increased by +9.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Increased by +100.00% | -43.71 M Decreased by -43.08% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -45.36 M Decreased by -40.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 35.00 M Increased by +N/A% | -7.13 M Increased by +79.22% | Decreased by -20.37% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -38.22 M Decreased by -145.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -11.30 M Decreased by -120.97% | -30.55 M Decreased by -249.37% | Increased by +270.29% Increased by +612.37% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -32.24 M Decreased by -3.35 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -34.30 M Decreased by -709.67% | Decreased by N/A% Decreased by N/A% |